The Food and Drug Administration (FDA) has granted NYX-2925 (Aptinyx) Fast Track designation for the potential treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN).

The company announced its intention to advance the development of NYX-2925 in neuropathic pain based on successful results from preclinical studies. Its safety and tolerability is now currently being evaluated in a randomized, double-blind, placebo-controlled, Phase 1 trial in healthy volunteers. Aptinyx intends to initiate a Phase 2 study in 2017.

NYX-2925 is an oral, small-molecule modulator of the N-methyl-D-aspartate (NMDA) receptor designed to enhance synaptic plasticity or strengthen the network for neural cell communication.


Continue Reading

Related Articles

Reference

Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy [news release]. Evanston, Ill; Aptinyx Newsroom. September 13, 2016. 

This article originally appeared on MPR